Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

MindMed achieves positive topline results in phase 2b clinical trial

MindMed has announced positive topline results from its phase 2b clinical trial of MM-120 in generalized anxiety disorder, according to a company press release.

The future of lymphoma treatment

Araris currently focuses on oncological advancements. Philipp Spycher, the Co-Founder and CSO, leads this strategic vision, driving a shift in targeted cancer therapies.

Managing Raw Material Variability for Autologous Cell Therapies

The most obvious variability, according to Akihiro Ko, CEO and cofounder of Elixirgen Therapeutics, is the disease severity and the condition of each patient.

Accelerating Drug Development With Real World Data

This was more than an exercise in academic research. Driven by the recognition that vaccines and immunotherapy were not as effective as expected, the newly minted DeMuth co-founded Elicio Therapeutics, Inc. to explore why that was.

The Next Ozempic or Wegovy… But Without the Injection? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma

What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.

The role of STRIs in cancer

eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance to treatment.

targeted oncology

New Phase 1 Findings Show Promise of Cancer Vaccines in KRAS Mutations

Elicio Therapeutics, outlined the SITC presentation on ELI-002 and plans for future cancer vaccine development.

targeted oncology

New Phase 1 Findings Show Promise of Cancer Vaccines in KRAS Mutations

The reason that I joined Elicio was in part because my father had KRAS-mutated colorectal cancer.